Inhibition of SIRT1 protein may hold promise for treatment of metastatic Ewing sarcoma

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), led by Oscar Martínez Tirado participated in an international study which suggests inhibition of Sirtuin1 (SIRT1) protein as a future treatment option for metastatic Ewing sarcoma. The results of the study were published in the journal Cancer Research.



from The Medical News http://ift.tt/1CWT2jv